[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"uterine-myoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:uterine-myoma":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,48,73,101],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":4},"100650342","terlipressin-vs-placebo-to-reduce-bleeding-in-fibroid-surgery-100650342",false,"NCT07746349","Terlipressin vs Placebo to Reduce Bleeding in Fibroid Surgery","Efficacy of Subcapsular Diluted Terlipressin Versus Placebo in Reducing Intraoperative Blood Loss During Myomectomy: A Randomized, Double-Blind, Placebo-Controlled Trial","Inclusion Criteria:\n\n* Symptomatic uterine fibroid(s) with an indication for myomectomy, including menorrhagia, pelvic pain\u002Fpressure, or infertility\n* Largest myoma diameter between 4 and 10 cm\n* Baseline hemoglobin ≥ 9 g\u002FdL\n* Not pregnant at the time of enrollment\n* Negative urine pregnancy test or last menstrual period within 4 weeks\n* Willing and able to provide written informed consent\n\nExclusion Criteria:\n\n* History of bleeding disorders or coagulopathy\n* Current anticoagulant or antiplatelet therapy\n* Known hypersensitivity or contraindication to terlipressin\n* Uncontrolled hypertension\n* Severe cardiac arrhythmia\n* Uncontrolled ischemic heart disease\n* Peripheral vascular disease\n* Pregnancy or suspected pregnancy\n* Previous myomectomy\n* Concurrent pelvic pathology requiring additional surgical intervention\n* Treatment with a GnRH agonist or ulipristal acetate within the 3 months preceding surgery\n* Suspected uterine malignancy, such as leiomyosarcoma\n* Inability to understand or provide informed consent","FEMALE",{"count":18,"type":19},80,"ESTIMATED","INTERVENTIONAL",[22],"NA","A myomectomy is a surgery to remove noncancerous growths (fibroids) from the uterus while keeping the uterus in place. This surgery can cause significant blood loss. Terlipressin is a medicine that narrows blood vessels and may help reduce bleeding.\n\nThis study will test whether injecting a diluted terlipressin solution under the outer covering of the fibroid, before it is removed, reduces the amount of blood lost during surgery, compared to an inactive solution (placebo). Women scheduled for myomectomy will be randomly assigned to receive either terlipressin or placebo. Neither the patients nor the surgical team will know which one was given until the study is finished. The main question this study will answer is how much blood is lost during surgery in each group.",[25,26,27],"Uterine Fibroids (Leiomyoma)","Uterine Myoma","Leiomyoma",[29,30,31,32,33,34,35],"Terlipressin","Myomectomy","Uterine Fibroids","Subcapsular Injection","Intraoperative Blood Loss","Vasopressin Analog","Placebo-Controlled Trial","NOT_YET_RECRUITING","2026-07-31",{"date":39,"type":40},"2026-08-05","ACTUAL",{"date":42,"type":19},"2026-08-01",{"date":44,"type":19},"2027-01",{"name":46,"class":47},"Sevil Cankaya","OTHER",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":20,"phases":58,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100566666","safety-and-efficacy-of-using-a-novel-full-visual-access-platform-system-in-transvaginal-hysterectomy-100566666","NCT06658145","Safety and Efficacy of Using a Novel Full Visual Access Platform System in Transvaginal Hysterectomy","The Establishment and Clinical Study of the Whole Visual VNOTES Approach Platform","Inclusion Criteria:\n\n1. Female patients ≤ 60years old\n2. Patients requiring total hysterectomy (with or without bilateral adjuncts or salpingectomy) due to uterine fibroids\n3. BMI ranges from 18.5 to 27.9kg\u002Fm2;\n4. Informed consent signed by the subject himself or his legal representative.\n\nExclusion Criteria:\n\n1. Pregnant and lactating women;\n2. asexual life history, vaginal malformations or adhesions, postmenopausal vaginal atrophy and stenosis;\n3. Preoperative examination for malignant possibility\n4. Uterine volume ≥20 weeks, history of pelvic inflammatory disease, severe endometriosis, degree III or IV uterine prolapse; Previous surgical history of intestinal obstruction, recurrent pelvic inflammatory disease, pelvic tuberculosis, and pelvic abdominal tumor; Gynecological examination of the uterine and rectal fossa is completely closed;\n5. Patients known to have severe hepatic or renal dysfunction;\n6. Patients with known blood disorders, coagulation disorders, active bleeding at any site, or bleeding propensity;\n7. complicated with serious diseases of central nervous system, cardiovascular system, liver and kidney, digestive tract, respiratory system, endocrine and metabolism (thyroid disease, Cushing\\'s syndrome, hyperprolactinemia), skeletal and muscular system and mental disorders;\n8. patients with acute infection;\n9. Known to have participated in any other clinical trial or taken hormone therapy within 3 months;\n10. who cannot sign the informed consent;\n11. For those with known or suspected poor compliance who could not complete the trial.","60 Years",{"count":57,"type":19},94,[22],"The modified vNOTES hysterectomy was accomplished and validated for efficacy and safety using a multi-access vaginal confinement instrument with a fully visualised vaginal access platform.",[26,61],"Surgery, Laparoscopic","RECRUITING","2025-02-10",{"date":65,"type":40},"2025-02-12",{"date":67,"type":19},"2025-02",{"date":69,"type":19},"2027-06",{"name":71,"class":47},"China-Japan Friendship Hospital",1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":72},"100577955","construction-of-a-model-for-the-differential-diagnosis-of-sarcomamyoma-based-on-the-radiomics-features-single-center-observational-study-100577955","NCT06805019","Construction of a Model for the Differential Diagnosis of SArcoma\u002Fmyoma Based on the RAdiomics Features: Single-center Observational Study","SARA","Inclusion Criteria:\n\n* Histological diagnosis of uterine sarcoma or myoma\n* Patients with pre-operative CT performed for diagnostic suspicion no more than 30 days before surgery\n* Age between 18 and 80 years\n* Patients followed in the clinical care path in our center\n* Obtaining informed consent\n\nExclusion Criteria:\n\n* Low quality of CT images.\n* Patients affected by other active neoplasms or diagnosed less than 5 years before the diagnosis of uterine sarcoma or myoma.","18 Years","80 Years",{"count":83,"type":19},176,"OBSERVATIONAL","Uterine sarcomas are rare and aggressive tumors originating from the muscular wall of the uterus. They have a high risk of recurrence and death, regardless of the stage of the disease at diagnosis. The therapy is surgical and involves hysterectomy preferably via laparotomy in consideration of the high risk of neoplastic dissemination through the rupture and fragmentation of the neoplasm as occurs through removal by other surgical routes which involve core drilling of the mass (laparoscopic, vaginal , hysteroscopic).\n\nUterine myoma represents a very frequent benign pathology in women, with an incidence of approximately 70%-80%. Asymptomatic cases do not require treatment, while symptomatic cases can be treated through the administration of generally antiestrogenic drugs to block growth and symptoms. Only a small part is removed surgically.\n\nCurrently the diagnosis of uterine sarcoma is almost always defined in the post-operative setting with the definitive histological examination, due to the lack of typical sonographic and radiological characteristics of certainty capable of differentiating benign neoplastic forms (myoma) from malignant ones of the uterus (sarcoma).\n\nMagnetic resonance imaging is currently the most reliable imaging modality for characterizing such uterine masses. Unfortunately, although it offers useful information, it is not able to discriminate with good precision a benign uterine lesion from a malignant one.\n\nCT is a method widely used in the staging of oncological diseases and therefore also in sarcomas. It is usually prescribed when there is an ultrasound doubt of a sarcoma before proceeding with surgery.\n\nHowever, although it is important in the definition of secondaries, it has very low sensitivity (60%) and specificity in the differential diagnosis between sarcoma and myoma.\n\nRadiomics is a novel approach that translates medical images into data by extracting a large number of quantitative features describing tissue characteristics, shape and texture, combining quantitative data analysis with biological and clinical endpoint.\n\nCapturing information from imaging that goes beyond the different biomedical imaging formats themselves is the great promise of this growing field.\n\nThe application of radiomics analysis to CT with the aim of preoperatively discriminating between sarcoma (malignant) and myoma (benign) could be a valid support in the preoperative evaluation and therapeutic decision-making process in order to personalize the most appropriate therapeutic approach .",[87,26],"Uterine Sarcoma",[89,90,91],"uterine sarcoma","uterine myoma","radiomic","2025-01-28",{"date":94,"type":40},"2025-02-03",{"date":96,"type":40},"2022-11-07",{"date":98,"type":19},"2025-06-30",{"name":100,"class":47},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":108,"minAge":109,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":20,"phases":112,"briefSummary":113,"conditions":114,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":72},"100554299","binaural-sound-for-remimazolam-maintenance-100554299","NCT06497283","Binaural Sound for Remimazolam Maintenance","The Effect of Intraoperative Binaural Sound on Remifentanil Dose Required for General Anesthesia Using Remimazolam: a Randomized, Placebo-controlled Trial","Inclusion Criteria:\n\n1. Patients scheduled for general anesthesia\n2. Patients aged 20-60\n3. Patients with American Society of Anesthesiologist physical status classification 1-2\n4. Patients with ideal body weight 50-80 kg\n\nExclusion Criteria:\n\n1. Patients with hearing disability\n2. Patients using opioids or sedatives in 1 week\n3. Patients who are dependent for alcoholics or drugs\n4. Patients with hypersensitivities to remimazolam or remifentanil\n5. Patients with arrhythmia, cardiovascular disease, heart failure, or hypovolemia\n6. Patients with liver failure","ALL","20 Years",{"count":111,"type":19},72,[22],"It is important to decrease the remifentanil dose for general anesthesia maintenance when using remimazolam. We will evaluate the effect of binaural sound on general anesthesia maintenance with remimazolam infusion.",[115,116,26],"General Anesthesia","Prostate Cancer Stage","2024-08-07",{"date":119,"type":40},"2024-08-09",{"date":121,"type":40},"2024-07-12",{"date":123,"type":19},"2025-02-28",{"name":125,"class":47},"Gangnam Severance Hospital"]